#United States #Madison #iPSC #BrainXell #sensory neurons

BrainXell Launches Innovative Human iPSC-Derived Sensory Neurons

Madison, Wisconsin-based BrainXell has announced an exciting advancement in neuroscience with its launch of human induced pluripotent stem cell (iPSC)-derived sensory neurons. This scalable cellular platform aims to facilitate functional studies in pain biology, sensory transduction, and ion channel pharmacology, providing researchers with vital tools to investigate the complexities of human sensory neuron biology.

The new sensory neurons exhibit a robust expression of key sensory neuron genes and proteins. These include essential voltage-gated sodium channels such as Nav1.7, Nav1.8, and Nav1.9, as well as transient receptor potential (TRP) channels TRPV1 and TRPM8. Additionally, they express the purinergic receptor P2RX3 and lineage markers like PRPH, ISL1, and POU4F1. This extensive gene and protein expression profile makes the cells highly relevant for studies on pain signaling and drug development aimed at analgesic discovery.

Dr. Semra Sahin, an Applications Scientist at BrainXell, said, "Human sensory neuron biology is highly complex, particularly when studying functional responses associated with pain signaling and ion channel activity. Our goal with this platform was to deliver a reproducible human model that combines strong molecular identity with functional responsiveness. This enables researchers to generate more predictive data across pharmacology and translational neuroscience workflows."

Addressing Limitations of Traditional Models

BrainXell's platform addresses a number of limitations found in traditional sensory neuron models. It integrates advanced controlled differentiation workflows with scalable manufacturing and rigorous quality control processes. The production demonstrates consistent lot-to-lot performance, supported by stable quantitative PCR (qPCR) results for crucial sensory neuron markers, ensuring reliable experimental outcomes.

Functional validation studies show that these sensory neurons respond effectively to canonical sensory agonists and various stimuli. This confirms their potential for use in nociception research, sensory signaling pathways, and ion channel pharmacology that mirrors physiologically relevant human biology, which has often been a challenge in previous models.

Launch Presentation on Scientist.com

Researchers will have the chance to preview this innovative product during a presentation set for Thursday, April 2 on Scientist.com. Dr. Semra Sahin and Business Development Manager Matt Mandeville will present characterization and functional performance data during this featured session, allowing attendees to understand the full capabilities of these sensory neurons.

About BrainXell

BrainXell focuses on developing and manufacturing human iPSC-derived neural cells, disease models, and assay services aimed at improving experimental reproducibility and providing heightened translational insights across the fields of neuroscience research and drug discovery. As the complexity and need for realistic human models grow in scientific research, BrainXell is poised to lead the charge with their groundbreaking solutions.

This launch represents a significant step towards enhancing the quality and impact of research in pain biology and sensory processing. As researchers seek to unravel the intricacies of sensory neuron function, tools like BrainXell's iPSC-derived sensory neurons will likely play a critical role in driving forward our understanding of pain mechanisms and the development of new therapeutic strategies.